文献速递MDS 与骨髓增殖性肿瘤

阿扎胞苷治疗后克隆大小预测骨髓增生异常综合征及相关髓系肿瘤患者的长期结局

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
PubMed 文献 · Blood Adv · 2023-01-01

该研究纳入449例骨髓增生异常综合征或相关髓系肿瘤患者,对治疗前(449例)和治疗后(289例)骨髓样本进行靶向捕获测序,评估基因突变及其治疗后克隆大小对疗效和总生存的影响。多打击TP53突变、EZH2突变和DDX41突变联合年龄、高危核型、低血小板和高原始细胞计数可独立预测总生存;治疗后克隆大小与IWG疗效显著相关(P<.001),联合IWG疗效可进一步改善预后模型预测能力。

要点

  • 多打击TP53突变(HR 2.03)、EZH2突变(HR 1.71)和DDX41突变(HR 0.33)可独立预测总生存。
  • 治疗后克隆大小与IWG疗效显著相关(P<.001,趋势检验),但DDX41突变克隆例外。
  • IWG疗效联合治疗后克隆大小可改善分子预后模型IPSS-M的预测能力(c-index 0.688 vs 0.653,P<.001)。

核心结论

  • 评估治疗后克隆大小联合治疗前突变谱和IWG疗效有助于更好地对接受阿扎胞苷治疗的骨髓增生异常患者进行预后分层。

研究设计与样本

  • 研究纳入449例骨髓增生异常综合征或相关髓系肿瘤患者,对治疗前(n=449)和治疗后(n=289)骨髓样本进行靶向捕获测序。

主要发现

  • 多打击TP53突变(HR 2.03;95%CI 1.42-2.91;P<.001)、EZH2突变(HR 1.71;95%CI 1.14-2.54;P=.009)和DDX41突变(HR 0.33;95%CI 0.17-0.62;P<.001)联合年龄、高危核型、低血小板和高原始细胞计数可独立预测总生存。
  • 治疗后克隆大小(涵盖所有驱动基因)与IWG疗效显著相关(P<.001,趋势检验),但DDX41突变克隆的治疗后克隆大小不预测IWG疗效。
  • IWG疗效联合治疗后克隆大小可改善原始模型及分子IPSS-M的预测能力(c-index 0.688 vs 0.653;P<.001,似然比检验)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their posttreatment clone size. We enrolled a total of 449 patients with MDS or related myeloid neoplasms. They were analyzed for gene mutations in pretreatment (n = 449) and posttreatment (n = 289) bone marrow samples using targeted-capture sequencing to assess the impact of gene mutations and their posttreatment clone size on treatment outcomes. In Cox proportional hazard modeling, multihit TP53 mutation (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.42-2.91; P < .001), EZH2 mutation (HR, 1.71; 95% CI, 1.14-2.54; P = .009), and DDX41 mutation (HR, 0.33; 95% CI, 0.17-0.62; P < .001), together with age, high-risk karyotypes, low platelets, and high blast counts, independently predicted OS. Posttreatment clone size accounting for all drivers significantly correlated with International Working Group (IWG) response (P < .001, using trend test), except for that of DDX41-mutated clones, which did not predict IWG response. Combined, IWG response and posttreatment clone size further improved the prediction of the original model and even that of a recently proposed molecular prediction model, the molecular International Prognostic Scoring System (IPSS-M; c-index, 0.653 vs 0.688; P < .001, using likelihood ratio test). In conclusion, evaluation of posttreatment clone size, together with the pretreatment mutational profile as well as the IWG response play a role in better prognostication of azacitidine-treated patients with myelodysplasia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nannya Y, Tobiasson M, Sato S, et al. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv. 2023. PMID: 36989067. doi:10.1182/bloodadvances.2022009564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。